Patrick Parfrey - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Patrick Parfrey

Showing results (71-80 of 90) with videos related to

Pageof 9

Sort By:

Journal of the American Society of Nephrology : JASN|October 24, 2008

Unified criteria for ultrasonographic diagnosis of ADPKDYork Pei, James Obaji, Annie Dupuis, et al.

Journal of the American Heart Association|April 25, 2016

Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marwa A Sabe, Brian Claggett, Emmanuel A Burdmann, et al.

Clinical Journal of the American Society of Nephrology : CJASN|May 28, 2017

Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled TrialRon Wald, Christian G Rabbat, Louis Girard, et al.

American Journal of Nephrology|December 15, 2017

Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy TrialFinnian R Mc Causland, Brian Claggett, Marc A Pfeffer, et al.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 10, 2024

Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic studyDavid Collister, Lonnie Pyne, Arrti A Bhasin, et al.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 21, 2016

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 14, 2020

Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trialsKai-Uwe Eckardt, Rajiv Agarwal, Youssef Mk Farag, et al.

Hypertension (Dallas, Tex. : 1979)|November 8, 2003

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and PreventionMark J Sarnak, Andrew S Levey, Anton C Schoolwerth, et al.

Circulation|October 29, 2003

Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overviewGlenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.

Pageof 9

Search research articles

Showing results (71-80 of 90) with videos related to

Sort By:

Pageof 9

Journal of the American Society of Nephrology : JASN|October 24, 2008

Unified criteria for ultrasonographic diagnosis of ADPKDYork Pei, James Obaji, Annie Dupuis, et al.

Journal of the American Heart Association|April 25, 2016

Clinical Journal of the American Society of Nephrology : CJASN|May 28, 2017

Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled TrialRon Wald, Christian G Rabbat, Louis Girard, et al.

American Journal of Nephrology|December 15, 2017

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 10, 2024

Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic studyDavid Collister, Lonnie Pyne, Arrti A Bhasin, et al.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 21, 2016

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 14, 2020

Hypertension (Dallas, Tex. : 1979)|November 8, 2003

Circulation|October 29, 2003

Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overviewGlenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.

Pageof 9